1.Glaucomatocyclitic Crisis.
Hong Bok KIM ; Jung Hyub OH ; Yong Beum KIM ; Oh Woong KWON
Journal of the Korean Ophthalmological Society 1977;18(4):369-371
The glaucomatocyclitic crisis was first described by Posner and Schlossman in 1948, and belongs to the classification of secondary open angle glaucoma. It is unilateral and recurrent. and characterized by minimal inflammatory signs and symptoms. The inflammation may be confined to the trabecular mesh work. The facility of outflow reduced while attacks last from a few hours to over 2 weeks. Etiopathogenic nature of glaucomatocyclitic crisis is not clear but recently the role of allergy is suggested in this disease entity. A 35 year old man was found to have a glaucomatocyclitic crisis in his right eye that was treated with systemic diamox and topical corticosteroid.
Acetazolamide
;
Adult
;
Classification
;
Glaucoma, Open-Angle
;
Humans
;
Hypersensitivity
;
Inflammation
2.Retraction: Risk Factors for Post-ERCP Pancreatitis after Needle Knife Sphincterotomy following Repeated Probing.
Jun Kyu LEE ; Joo Kyoung PARK ; Sang Hyub LEE ; Won Jae YOON ; Kwang Hyuck LEE ; Ji Kon RYU ; Yong Tae KIM ; Yong Bum YOON
Korean Journal of Gastrointestinal Endoscopy 2008;37(1):82-82
No abstract available.
3.Liver disease in KOrea HBsAg carriers with end stage renal disease.
Chan Shin PARK ; Chae Yoon CHON ; Ki Yong KIM ; Heung Soo KIM ; Kwang Hyub HAN ; Kyu Hun CHOI ; Ho Yung LEE ; Chan Il PARK ; Dae Suk HAN
Korean Journal of Nephrology 1993;12(2):136-143
No abstract available.
Hepatitis B Surface Antigens*
;
Kidney Failure, Chronic*
;
Korea*
;
Liver Diseases*
;
Liver*
4.MicroRNA 141 Expression Is a Potential Prognostic Marker of Biliary Tract Cancers.
Jaihwan KIM ; Ji Kon RYU ; Sang Hyub LEE ; Yong Tae KIM
Gut and Liver 2016;10(5):836-841
BACKGROUND/AIMS: In recent years, a large number of micro-ribonucleic acids (miRNAs) have been identified as putative prognostic biomarkers for solid cancers because of their role in controlling the expression of oncogenes and tumor suppressor genes. The aim of this study was to verify the utility of miRNA 141 as a prognostic biomarker of biliary tract cancers. METHODS: From June 2010 to June 2012, common bile duct cancer tissue samples and matched noncancerous tissues from the ampulla of Vater were obtained from patients with biliary tract cancer undergoing endoscopic retrograde cholangiopancreatography. Using quantitative real-time polymerase chain reaction assays, we measured the mean relative expression levels of miRNA 141 in both groups of tissues. Overexpression of miRNA 141 was defined as a greater than 2-fold increase in expression levels as determined by the 2−ΔΔCt method. RESULTS: In a cohort of 38 patients with biliary tract cancers (seven gallbladder, 13 hilar, and 18 distal bile duct cancers), 26 patients (68.4%) were male, and the median age was 69.5 (52 to 85) years. Nineteen patients (50%) had undergone R0 resection procedures, including three Whipple operations, seven pylorus-preserving pancreaticoduodenectomies, six bile duct resections, and three extended lobectomies. Among the patients who had undergone R0 resection, the overexpression of miRNA 141 was significantly associated with shorter disease-free survival and a greater risk of angiolymphatic invasion. Among the patients who did not undergo R0 resection, miRNA 141 overexpression was significantly associated with reduced overall survival. CONCLUSIONS: Overexpression of miRNA 141 is an indicator of a poor prognosis in patients with biliary tract cancer, suggesting that miRNA 141 may be a valuable prognostic biomarker of this disease.
Ampulla of Vater
;
Bile Ducts
;
Biliary Tract Neoplasms*
;
Biliary Tract*
;
Biomarkers
;
Cholangiopancreatography, Endoscopic Retrograde
;
Cohort Studies
;
Common Bile Duct
;
Disease-Free Survival
;
Gallbladder
;
Genes, Tumor Suppressor
;
Humans
;
Male
;
Methods
;
MicroRNAs*
;
Oncogenes
;
Pancreaticoduodenectomy
;
Prognosis
;
Real-Time Polymerase Chain Reaction
5.Analysis of Risk Factors for Myringosclerosis Formation after Ventilation Tube Insertion
Eung Hyub KIM ; Ki Wan PARK ; Seung Hun LEE ; Bong Jik KIM ; Yong-Ho PARK
Journal of Korean Medical Science 2020;35(13):e83-
Background:
This study examined possible risk factors for myringosclerosis formation after ventilation tube insertion (VTI).
Methods:
A retrospective study was performed in a single tertiary referral center. A total of 582 patients who underwent VTI were enrolled in this study. Patients were divided into two groups based on the presence or absence of myringosclerosis: MS+ and MS−. Characteristics of patients were collected through medical chart review; these included age, gender, nature and duration of effusion, type of ventilation tube (VT), duration and frequency of VTI, incidence of post-VTI infection, incidence of intraoperative bleeding, and presence of postoperative perforation. Incidences of risk factors for myringosclerosis and the severity of myringosclerosis in association with possible risk factors were analyzed.
Results:
Myringosclerosis developed in 168 of 582 patients (28.9%) after VTI. Patients in the MS+ group had an older mean age than those in the MS− group. The rates of myringosclerosis were higher in patients with older age, serous otitis media, type 2 VT, post-VTI perforation, and frequent VTI. However, there were no differences in occurrence of myringosclerosis based on gender, duration of effusion, duration of VT placement, incidence of post-VTI infection, or incidence of intraoperative bleeding. The severity of myringosclerosis was associated with the duration of effusion and frequency of VTI.
Conclusion
Older age, serous effusion, type 2 VT, presence of post-VTI perforation, and frequent VTI may be risk factors for myringosclerosis after VTI; the severity of myringosclerosis may vary based on the duration of effusion and frequency of VTI.
6.Objective Assessment of Surgical Restaging after Concurrent Chemoradiation for Locally Advanced Pancreatic Cancer.
Woo Hyun PAIK ; Sang Hyub LEE ; Yong Tae KIM ; Jin Myung PARK ; Byeong Jun SONG ; Ji Kon RYU
Journal of Korean Medical Science 2015;30(7):917-923
The role of neoadjuvant chemoradiation therapy in locally advanced pancreatic cancer (LAPC) is still controversial. The aim of this study was to evaluate surgical downstaging after concurrent chemoradiation therapy (CCRT) for LAPC by measuring the objective changes after treatment. From January 2003 through July 2011, 54 patients with LAPC underwent neoadjuvant CCRT. Computed tomography findings of the tumor size, including major vessel invasion, were analyzed before and after CCRT. Among the total recruited patients, 14 had borderline resectable malignancy and another 40 were unresectable before CCRT. After CCRT, a partial response was achieved in four patients. Stable disease and further disease progression were achieved in 36 and 14 patients, respectively. Tumor size showed no significant difference before and after CCRT (3.6 +/- 1.1 vs. 3.6 +/- 1.0 cm, P = 0.61). Vessel invasion showed improvement in two patients, while 13 other patients showed further tumor progression. Thirty-nine patients with unresectable malignancy and 11 patients with borderline resectable malignancy at time of initial diagnosis remained unchanged after CCRT. Four patients with borderline pancreatic malignancy progressed to an unresectable stage, whereas one unresectable pancreatic malignancy improved to a borderline resectable stage. Only one patient with borderline resectable disease underwent operation after CCRT; however, curative resection failed due to celiac artery invasion and peritoneal seeding. The adverse events associated with CCRT were tolerable. In conclusion, preoperative CCRT in LAPC rarely leads to surgical downstaging, and it could lower resectability rates.
Adenocarcinoma/radiography/therapy
;
Adult
;
Aged
;
Aged, 80 and over
;
Antimetabolites, Antineoplastic/therapeutic use
;
Antineoplastic Combined Chemotherapy Protocols/therapeutic use
;
Capecitabine/therapeutic use
;
Carcinoma, Pancreatic Ductal/*radiography/*therapy
;
Chemoradiotherapy/adverse effects/*methods
;
Combined Modality Therapy
;
Deoxycytidine/analogs & derivatives/therapeutic use
;
Disease Progression
;
Female
;
Fluorouracil/therapeutic use
;
Humans
;
Male
;
Middle Aged
;
Neoadjuvant Therapy
;
Neoplasm Staging
;
Pancreas/blood supply/pathology
;
Pancreatic Neoplasms/*radiography/*therapy
;
Retrospective Studies
;
Treatment Outcome
7.Long-term Survival in Patient with Metastatic Pancreatic Neuroendocrine Tumor Treated by Variable Treatment.
Hyung Chang KANG ; Ji Kon RYU ; Sang Hyub LEE ; Yong Tae KIM
Korean Journal of Pancreas and Biliary Tract 2017;22(3):141-146
A 46-year-old female with abnormal radiologic finding was diagnosed with pancreatic neuroendocrine tumor and multiple hepatic metastasis. Molecular targeted therapy (everolimus) and two times of transarterial chemoembolizations (TACE) were performed before pylorus-preserving pancreaticoduodenectomy (PPPD). After 2nd TACE and PPPD, grade 2 pancreatic neuroendocrine tumor was pathologically confirmed. Four times of additional TACE was done. After size increase of several probable hepatic metastasis in the both lobes of liver, laparoscopic left lateral sectionectomy of liver was performed. After two and half years of left lateral sectionectomy, 7th TACE was performed and the patients have survived without further disease progression. This case suggests that patients with pancreatic neuroendocrine tumor and hepatic metastasis can be treated by TACE, primary tumor resection, surgery for liver metastasis and molecular targeted therapy. Therefore, aggressive multidisciplinary approaches need to be considered for long term survival of patients with pancreatic neuroendocrine tumor with hepatic metastasis.
Disease Progression
;
Female
;
Humans
;
Liver
;
Middle Aged
;
Molecular Targeted Therapy
;
Neoplasm Metastasis
;
Neuroendocrine Tumors*
;
Pancreas
;
Pancreaticoduodenectomy
8.Sequence Analysis of 'a' Determinant in Two Patients with De Novo HBV Infection after Renal Transplantation.
Byung Hyun CHOE ; Kwang Hyub HAN ; Hyo Young CHUNG ; Yong Han PAIK ; Jung Il CHUNG ; Yoo Sun KIM ; Chae Yoon CHON ; Young Myoung MOON
The Korean Journal of Hepatology 1999;5(4):291-298
BACKGROUND/AIMS: HBV infection can be seen after organ transplantation. The presence of anti-Bs in serum means protection from HBV infection. If amino acids were mutated in 'a' determinant which was a common antigenic epitope of HBsAg, escape from humoral immunity can occur. Recently, in chronic HBV infected patients who received liver transplantation but reinfected by HBV, many authors reported mutations in 'a' determinant sequence. However, in renal transplantation, there were few reports about HBV infection and 'a' determinant mutation after transplantation. Therefore, we studied the incidence of HBV reinfection after renal transplantation and also tried to analyze 'a' determinant sequence in those patients. METHODS: We reviewed HBsAg-egative patients who received renal transplantation in our hospital, but turned HBsAg positive after transplantation. We selected two patients who were anti-Bs positive before transplantation but turned HBsAg positive after transplantation, and analyzed 'a' determinant of amino acid sequence of these patients. RESULTS: Among 1682 patients who were HBsAg negative before transplantation, 21 patients were turned HBsAg positive after transplantation. Among them, 6 patients were anti-Bs positive before transplantation. Sequence analysis of the 'a' determinant amino acid in two patients whose HBsAg turned positive after transplantation revealed no evidence of mutation in comparison with previously reported subtype 'a' determinant sequences. CONCLUSION: In renal transplantation, HBV could be reinfected in patients who had been anti-Bs positive before transplantation even without mutation in 'a' determinant region.
Amino Acid Sequence
;
Amino Acids
;
Hepatitis B Surface Antigens
;
Humans
;
Immunity, Humoral
;
Incidence
;
Kidney Transplantation*
;
Liver Transplantation
;
Organ Transplantation
;
Sequence Analysis*
;
Transplants
;
United Nations
9.A Case of Peliosis Hepatis, Diagnosed by Peritoneoscopic Liver Biopsy.
Young Myung MOON ; Jin Kyung KANG ; In Suh PARK ; Chae Yoon CHON ; Kwang Hyub HAN ; Sang Jin PARK ; Hee Yong MOON ; Kyeung Jin KIM
Korean Journal of Gastrointestinal Endoscopy 1995;15(1):110-117
Peliosis hepatis is characterized by the presence in the liver of blood-filled cavities, which may or may not be lined with sinusoidal cells. The individual cysts or cavities usually do not exceed several centimeters in diameter. The cysts are typically continuous with adjacent, more normal sinusoids, and they sometimes can be seen in continuity with hepatic venous tributaries. The lesion is usually diagnosed by gross or microscopic examination. When suspected, it can be diagnosed by percutaneous liver biopsy. In the past, peliosis hepatis is primarily associated with wasting diseases, such as tuberculosis, malignancy, and chronic suppurative infection. However, recently peliosis hepatis is seen most commonly in association with the administration of anabolic steroids or HIV infection. We report a case of peliosis hepatis that is diagnosed by peritoneoscopic live biopsy and not associated with known disease.
Biopsy*
;
HIV Infections
;
Laparoscopy
;
Liver*
;
Peliosis Hepatis*
;
Steroids
;
Tuberculosis
;
Wasting Syndrome
10.The Effect of Long-erm Lamivudine Therapy for Chronic Liver Disease due to Hepatitis B Virus.
Jin Suk KIM ; Kwang Hyub HAN ; Hyo Young CHUNG ; Sang Hoon AHN ; Yong Han PAIK ; Kwan Sik LEE ; Chae Yoon CHON ; Young Myoung MOON
The Korean Journal of Hepatology 1999;5(2):97-104
BACKGROUND/AIMS: We studied to evaluate the virological and biochemical responses to lamivudine and to detect YMDD mutants in patients who received long-erm lamivudine therapy. METHODS: We conducted a one-ear trial of lamivudine in 45 Korean patients with chronic liver disease due to hepatitis B virus. The patients were treated with a single oral average dose of 100 mg of lamivudine every day for 12 months. RESULTS: The suppression of serum HBV DNA was sustained in 77.8% of the patients and the normalization of serum ALT in 80%. The proportions of patients with HBeAg seroconversion were 25%. YMDD mutants were detected in 4 of 8 patients who showed sustained HBV DNA and serum ALT response (n=31) and in 3 of 8 patients who showed HBV DNA or serum ALT breakthrough (n=9). The response to lamivudine therapy in HBeAg-egative patients was excellent. CONCLUSION: Lamivudine therapy resulted in a significant virological and biochemical improvements and were well tolerated. But, YMDD mutants were detected during lamivudine therapy.
DNA
;
Hepatitis B e Antigens
;
Hepatitis B virus*
;
Hepatitis B*
;
Hepatitis*
;
Humans
;
Lamivudine*
;
Liver Diseases*
;
Liver*